mutation class

Small Mutation

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

343 sites for NCT04181060

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

bevacizumab, +1 more drug

targeted therapy

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

10 sites for NCT04816214

EGFR A763_Y764insFQEA, +7 more biomarkers

Non-Small Cell Lung Carcinoma

capmatinib, +1 more drug

targeted therapy

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

1 site for NCT04743505

EGFR A763_Y764insFQEA, +6 more biomarkers

Non-Small Cell Lung Carcinoma

bozitinib, +1 more drug

targeted therapy

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

40 sites for NCT03944772

EGFR A763_Y764insFQEA, +7 more biomarkers

Large Cell Lung Neuroendocrine Carcinoma, +2 more conditions

alectinib, +11 more drugs

chemotherapy, +2 more types

Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

33 sites for NCT04669899

ALK Fusion, +11 more biomarkers

Breast Carcinoma, +3 more conditions

JTX-8064, +1 more drug

immunotherapy

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type

afatinib

EGFR Codon 719 Missense, +4 more biomarkers

Non-Small Cell Lung Carcinoma

Metastatic

First line

afatinib

targeted therapy

afatinib

EGFR A763_Y764insFQEA, +4 more biomarkers

Non-Small Cell Lung Carcinoma

Advanced, +1 more state

First line

afatinib

targeted therapy

afatinib + cetuximab

EGFR A763_Y764insFQEA, +6 more biomarkers

Non-Small Cell Lung Carcinoma

Advanced, +1 more state

Subsequent line

afatinib, +1 more drug

targeted therapy

erlotinib

EGFR A763_Y764insFQEA, +5 more biomarkers

Non-Small Cell Lung Carcinoma

Advanced, +1 more state

First line

erlotinib

targeted therapy

gefitinib

EGFR A763_Y764insFQEA, +5 more biomarkers

Non-Small Cell Lung Carcinoma

Advanced, +1 more state

First line

gefitinib

targeted therapy

osimertinib

EGFR A763_Y764insFQEA, +5 more biomarkers

Non-Small Cell Lung Carcinoma

Advanced, +1 more state

First line

osimertinib

targeted therapy